Panitumumab and RAS, DIagnostically-useful Gene Mutation for mCRC).

clinical trial

Panitumumab and RAS, DIagnostically-useful Gene Mutation for mCRC). is …
instance of (P31):
clinical trialQ30612

External links are
P3098ClinicalTrials.gov IDNCT02394795

P6099clinical trial phasephase III clinical trialQ42824827
P17countryJapanQ17
P582end time2020-03-01
P4135maximum age79
P2899minimum age20
P1132number of participants823
P4844research interventionbevacizumabQ413299
leucovorin calciumQ27077063
fluorouracilQ238512
calcium oxalateQ412399
P1813short namePARADIGM
P580start time2015-04-01
P8363study typeinterventional studyQ78089383
P1476titleA Phase III, Randomized, Controlled Study of mFOLFOX6 + Bevacizumab Combination Therapy Versus mFOLFOX6 + Panitumumab Combination Therapy in Chemotherapy-naive Patients With KRAS/NRAS Wild-type, Incurable/Unresectable, Advanced/Recurrent Colorectal Cancer

Search more.